120 related articles for article (PubMed ID: 37171945)
1. MET Inhibits the Proliferation of EC Cells by Increasing MPA Sensitivity.
Sun F; Zhou J; Hao Y; Kuang L; Zhang B
Altern Ther Health Med; 2023 Jul; 29(5):334-341. PubMed ID: 37171945
[TBL] [Abstract][Full Text] [Related]
2. Metformin Enhances Nomegestrol Acetate Suppressing Growth of Endometrial Cancer Cells and May Correlate to Downregulating mTOR Activity In Vitro and In Vivo.
Cao C; Zhou JY; Xie SW; Guo XJ; Li GT; Gong YJ; Yang WJ; Li Z; Zhong RH; Shao HH; Zhu Y
Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31284427
[TBL] [Abstract][Full Text] [Related]
3. Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells.
Xie Y; Wang YL; Yu L; Hu Q; Ji L; Zhang Y; Liao QP
J Steroid Biochem Mol Biol; 2011 Sep; 126(3-5):113-20. PubMed ID: 21168492
[TBL] [Abstract][Full Text] [Related]
4. Metformin attenuates the production and proliferative effects of prolactin induced by medroxyprogesterone acetate during fertility-sparing treatment for endometrial cancer.
Gu W; Mitsuhashi A; Kobayashi T; Shozu M
BMC Cancer; 2022 Jul; 22(1):753. PubMed ID: 35820883
[TBL] [Abstract][Full Text] [Related]
5. NrCAM secreted by endometrial stromal cells enhances the progestin sensitivity of endometrial cancer cells through epigenetic modulation of PRB.
Cheng Y; Xie L; Xu Z; Hao M; Yang B; Shan W; Wang Y; Lv Q; Chen X
Cancer Gene Ther; 2022 Oct; 29(10):1452-1462. PubMed ID: 35388173
[TBL] [Abstract][Full Text] [Related]
6. 5-aza-2'-deoxycytidine improves the sensitivity of endometrial cancer cells to progesterone therapy.
Hu Q; Yu L; Chen R; Wang YL; Ji L; Zhang Y; Xie Y; Liao QP
Int J Gynecol Cancer; 2012 Jul; 22(6):951-9. PubMed ID: 22683940
[TBL] [Abstract][Full Text] [Related]
7. [Effect and regulation of metformin on endometrial carcinoma subline of progestin-resistance].
Niu YJ; Shi HR; Xie Y
Zhonghua Fu Chan Ke Za Zhi; 2016 Feb; 51(2):135-40. PubMed ID: 26917483
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor signaling pathway involved in progestin-resistance of human endometrial carcinoma: In a mouse model.
Xu Y; Tong J; Ai Z; Wang J; Teng Y
J Obstet Gynaecol Res; 2012 Dec; 38(12):1358-66. PubMed ID: 22612393
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effect of metformin and medroxyprogesterone 17‑acetate on the development of endometrial cancer.
Mu N; Dong M; Li L; Xia M; Qv L; Wang Y; Dong C; Chen Y; Zuo Y; Hou J; Xue F
Oncol Rep; 2018 Apr; 39(4):2015-2021. PubMed ID: 29393479
[TBL] [Abstract][Full Text] [Related]
10. miR-205 inhibits cell growth by targeting AKT-mTOR signaling in progesterone-resistant endometrial cancer Ishikawa cells.
Zhuo Z; Yu H
Oncotarget; 2017 Apr; 8(17):28042-28051. PubMed ID: 28427207
[TBL] [Abstract][Full Text] [Related]
11. Aberrant upregulation of CDK1 contributes to medroxyprogesterone acetate (MPA) resistance in cancer-associated fibroblasts of the endometrium.
Omar IS; Mat Adenan NA; Godoy A; Teo IH; Gunasagran Y; Chung I
Biochem Biophys Res Commun; 2022 Nov; 628():133-140. PubMed ID: 36084551
[TBL] [Abstract][Full Text] [Related]
12. Combination of metformin and RG7388 enhances inhibition of growth and induction of apoptosis of ovarian cancer cells through the PI3K/AKT/mTOR pathway.
Cui Y; Zhou J; Rong F
Biochem Biophys Res Commun; 2020 Dec; 533(4):665-671. PubMed ID: 33051060
[TBL] [Abstract][Full Text] [Related]
13. Progestin treatment decreases CD133+ cancer stem cell populations in endometrial cancer.
Guy MS; Qamar L; Behbakht K; Post MD; Sheeder J; Sartorius CA; Spillman MA
Gynecol Oncol; 2016 Mar; 140(3):518-26. PubMed ID: 26731726
[TBL] [Abstract][Full Text] [Related]
14. Knocking down FAM83B inhibits endometrial cancer cell proliferation and metastasis by silencing the PI3K/AKT/mTOR pathway.
Lin Q; Chen H; Zhang M; Xiong H; Jiang Q
Biomed Pharmacother; 2019 Jul; 115():108939. PubMed ID: 31079003
[TBL] [Abstract][Full Text] [Related]
15. Core Target and Key Signal Pathway of Xiaoluo in the Treatment of Thyroid Cancer.
Liang W; Zhang K; Sun Y; Chen L; Wang Z; Cheng W; Li W
Altern Ther Health Med; 2023 Jul; 29(5):400-409. PubMed ID: 37171951
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer.
Mitsuhashi A; Sato Y; Kiyokawa T; Koshizaka M; Hanaoka H; Shozu M
Ann Oncol; 2016 Feb; 27(2):262-6. PubMed ID: 26578736
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting the PI3K/Akt pathway reversed progestin resistance in endometrial cancer.
Gu C; Zhang Z; Yu Y; Liu Y; Zhao F; Yin L; Feng Y; Chen X
Cancer Sci; 2011 Mar; 102(3):557-64. PubMed ID: 21205080
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of long non-coding HOTAIR enhances the sensitivity to progesterone in endometrial cancer by epigenetic regulation of progesterone receptor isoform B.
Chi S; Liu Y; Zhou X; Feng D; Xiao X; Li W; Zhao Y; Wang H
Cancer Chemother Pharmacol; 2019 Feb; 83(2):277-287. PubMed ID: 30443761
[TBL] [Abstract][Full Text] [Related]
19. Medroxyprogesterone acetate causes the alterations of endoplasmic reticulum related mRNAs and lncRNAs in endometrial cancer cells.
Cao W; Gao W; Zheng P; Sun X; Wang L
BMC Med Genomics; 2019 Nov; 12(1):163. PubMed ID: 31718641
[TBL] [Abstract][Full Text] [Related]
20. Metformin Promotes Anti-tumor Biomarkers in Human Endometrial Cancer Cells.
Pabona JMP; Burnett AF; Brown DM; Quick CM; Simmen FA; Montales MTE; Liu SJ; Rose T; Alhallak I; Siegel ER; Simmen RC
Reprod Sci; 2020 Jan; 27(1):267-277. PubMed ID: 32046384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
